CRYOPORT, INC. Gain on Business Interruption Insurance Recovery
CRYOPORT, INC. (CYRX) reported Gain on Business Interruption Insurance Recovery of $2.60 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainOnBusinessInterruptionInsuranceRecovery · last filed 2024-11-07
- CRYOPORT, INC. gain on business interruption insurance recovery for the quarter ending 2023-09-30 was $0.00.
| Period end | Gain on Business Interruption Insurance Recovery 3 month | Gain on Business Interruption Insurance Recovery 6 month | Gain on Business Interruption Insurance Recovery 9 month |
|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.60M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $2.60M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |